Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
Pharmacist called to report 25 year old male was administered first dose of GARDASIL 9 in APR2023 and second dose in JUN2023 but has not yet received their third dose.; No adverse event; This spontaneous report has been received from a pharmacist concerns a 25-year-old male patient. No information regarding the patient's medical history, previous drug reactions or allergies and concomitant medications was provided. On an unknown date in April 2023, the patient received first dose of HPV rL1 6 11 16 18 31 45 52 58 VLP vaccine (yeast) (GARDASIL 9) suspension for injection (strength, exact dose, anatomical route of administration, lot number and expiration date were not reported) and second dose in June 2023, but has not yet received their third dose (inappropriate schedule of product administration). No additional adverse event. Additional information is not expected.